CRISPR/Cas9 Edited RAS & MEK Mutant Cells Acquire BRAF and MEK Inhibitor Resistance with MEK1 Q56P Restoring Sensitivity to MEK/BRAF Inhibitor Combo and KRAS G13D Gaining Sensitivity to Immunotherapy

CRISPR/Cas9 Edited RAS & MEK Mutant Cells Acquire BRAF and MEK Inhibitor Resistance with MEK1 Q56P Restoring Sensitivity to MEK/BRAF Inhibitor Combo and KRAS G13D Gaining Sensitivity to Immunotherapy

<i>BRAF V600E</i> mutation drives uncontrolled cell growth in most melanomas. While <i>BRAF V600E</i> tumors are initially responsive to BRAF inhibitors, prolonged treatment results in inhibitor resistance and tumor regrowth. Clinical data have linked the <i>NRAS Q61K&l...

Full description

Bibliographic Details
Main Authors: Elizabeth Turner, Luping Chen, John G. Foulke, Zhizhan Gu, Fang Tian
Format: Article
Language:English
Published: MDPI AG 2022-11-01
Series:Cancers
Subjects:
drug resistance
BRAF
KRAS
MEK
CRISPR/Cas9
Online Access:https://www.mdpi.com/2072-6694/14/21/5449

Internet

https://www.mdpi.com/2072-6694/14/21/5449

Similar Items